Amiodaron

Amiodaron wurde ursprünglich in den 60er Jahren als Pharmakon zur Therapie der Angina pectoris eingeführt. Erst später wurden die antiarrhythmischen Eigenschaften von Amiodaron erkannt [1-3].

Literatur

• 1 Charlier R. Récherches dans la séries des benzfurannes. VII. Etude pharmacologique préliminaire du butyl-2(diiodo-3’,5’-B-N-diethylaminoethoxy-4’ benzoyl)-3 benzfuranne.  Arch Int Pharmacodyn. 1962;  139 255-262
• 2 Singh B N. Amiodarone: historical development and pharmacologic profile.  Am Heart J. 1983;  106 788-797
• 3 Vastesaeger M. Etude clinique d’une nouvelle médication antiangoreuse.  Acta Cardiol (Brux). 1964;  22 483
• 4 Lai L P, Su M J, Tseng Y Z, Lien W P. Sensitivity of the slow component of the delayed rectifier potassium current (IKs) to potassium channel blockers: Implications for clinical reverse use-dependent effects.  J Biomed Sci. 1999;  6 251-259
• 5 Sanguinetti M C, Jurkiewicz N K. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.  J Gen Physiol. 1990;  96 195-215
• 6 Julian D G, Camm A J, Frangin G, Janse M J, Munoz A, Schwartz P J, Simon P. Investigators: EMIAT. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT.  Lancet. 1997;  349 667-674
• 7 Amiodarone Trials Meta-analysis Investigators . The effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual patient data on 6500 patients from randomized trials.  Lancet. 1997;  350 1417-1424
• 8 Hohnloser S H, Klingenheben T, Singh B N. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.  Ann Intern Med. 1994;  121 529-535
• 9 Cairns J A, Connolly S J, Roberts R S, Gent M, Investigators T C. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT.  Lancet. 1997;  349 675-682
• 10 Yin Y L, Perret G Y, Nicolas P, Vassy R, Uzzan B, Tod M. In vivo effects of amiodarone on cardiac beta-adrenoceptor density and heart rate require thyroid hormones.  J Cardiovasc Pharmacol. 1992;  19 541-545
• 11 Latham K R, Sellitti D F, Goldstein R E. Interaction of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors.  J Am Coll Cardiol. 1987;  9 872-876
• 12 Drvota V, Blange I, Haggblad J, Sylven C. Desethylamiodarone prolongation of cardiac repolarization is dependent on gene expression: a novel antiarrhythmic mechanism.  J Cardiovasc Pharmacol. 1998;  32 654-661
• 13 van Beeren H C, Bakker O, Wiersinga W M. Structure-function relationship of the inhibition of the 3,5,3’-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs.  Endocrinology. 1996;  137 2807-2814
• 14 Aanderaud S, Sundsfjord J, Aarbokke J. Amiodarone inhibits the conversion of thyroxin to triiodothyronine inisolated rat heaptocytes.  Endocrinology. 1984;  115 1605-1608
• 15 Krenning E P, Docter R, Bernard B, Visser T, Hennemann G. Decreased transport of thyroxine (T4), 3,3’,5-triiodothyronine (T3) and 3,3’,5’-triiodothyronine (rT3) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs.  FEBS Lett. 1982;  140 229-233
• 16 Connolly S J. Meta-analysis of antiarrhythmic drug trials.  Am J Cardiol. 1999;  84 90R-93R
• 17 Connolly S J. Evidence-based analysis of amiodarone efficacy and safety.  Circulation. 1999;  100 2025-2034
• 18 Herbette L G, Trumbore M, Chester D W, Katz A M. Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: propranolol, nimodipine and amiodarone.  J Mol Cell Cardiol. 1988;  20 373-378
• 19 Hein L, Lüllmann-Rauch R, Mohr K. Human accumulation potential of xenobiotics: potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis.  Xenobiotica. 1990;  20 1259-1267
• 20 Holt D W, Tucker G T, Jackson P R, Storey G CA. Amiodarone pharmacokinetics.  Am Heart J. 1983;  106 840-847
• 21 Adams P C, Holt D W, Storey G CA, Morley A R, Callaghan J, Path M RC, Campbell R WF. Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy.  Ther Prev Pharmacol. 1985;  72 1064-1075
• 22 Pollak P T, Bouillon T, Shafer S L. Population pharmacokinetics of long-term oral amiodarone therapy.  Clin Pharmacol Ther. 2000;  67 642-652
• 23 Mason J W. Amiodarone.  N Engl J Med. 1987;  316 455-466
• 24 Francois J. Cornea verticillata.  Bull Soc Belge Ophthalmol. 1968;  150 656-670
• 25 D’Amico D J, Kenyon K R, Ruskin J N. Amiodarone keratopathy: drug-induced lipid storage disease.  Arch Ophthalmol. 1981;  99 257-261
• 26 Pollak P T. Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations.  Am J Cardiol. 1999;  84 37R-45R
• 27 Vorperian V R, Havighurst T C, Miller S, January C T. Adverse effects of low dose amiodarone: a meta-analysis.  J Am Coll Cardiol. 1997;  30 791-798
• 28 Loh K C. Amiodarone-induced thyroid disorders: A clinical review.  Postgrad Med J. 2000;  76 133-140
• 29 Hennersdorf M G, Strauer B E. Herzrhythmusstörungen bei Hyperthyreose.  Dtsch Med Wschr. 2000;  125 637-641

Korrespondenz